Ciclosporin fails to demonstrate protection from neuronal damage during thrombolysis
Pharmacological reperfusion in acute ischaemic stroke may cause neuronal damage, so there is interest in adjuvant neuroprotective strategies. A phase II study of ciclosporin, administered intravenously at the same time as thrombolysis, has failed to demonstrate a benefit for the primary endpoint, infarct volume at 30 days.
The study, published in Neurology (online, 6 May 2015), included 127 patients with acute ischaemic stroke who were eligible for thrombolytic therapy. Although ciclosporin was not effective in reducing infarct size overall, a post hoc analysis suggested that treatment may be beneficial in a subgroup of patients with proximal occlusion and effective recanalisation, in whom infarct volume was significantly reduced with ciclosporin versus placebo (14.9ml vs 48.3ml).
“Efficacy needs to be confirmed in larger studies focusing on this specific patient group,” the authors conclude.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068547
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now